Class 09 · Cosmetic / topical peptides · SNAP-25 / SNARE-mimetic · Octapeptide · Anti-expression-line · Not a drug
SNAP-8acetyl octapeptide-3 — the topical "Botox-like" cosmetic peptide
SNAP-8 is a synthetic peptide used in anti-aging skin-care products — serums and creams aimed at the look of expression lines like forehead and crow's-feet wrinkles. It's an extension of the better-known cosmetic peptide Argireline, and is sometimes marketed as "topical Botox." That label oversells it: it is a cosmetic ingredient, not a drug or an injection, the independent evidence for SNAP-8 specifically is thin, and how well any of it penetrates skin is a real open question. It should not be expected to work like an actual Botox treatment.
A synthetic octapeptide (Acetyl Octapeptide-3, commonly Ac-EEMQRRAD-NH₂) in the SNAP-25/SNARE-mimetic cosmetic family — an extended relative of acetyl hexapeptide-8 (Argireline). The proposed action is partial interference with SNARE-complex assembly to soften the appearance of dynamic wrinkles. It is a topical cosmetic ingredient with no FDA-approved therapeutic indication; direct human evidence for SNAP-8 itself is limited and much of the mechanistic confidence is extrapolated from Argireline and in-vitro SNARE work.
SNAP-8 / Acetyl Octapeptide-3 — commonly represented as Ac-Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp-NH₂ (Ac-EEMQRRAD-NH₂). Identity caution: public records conflict — PubChem (CID 71587832) lists C₄₂H₇₂N₁₆O₁₅S, MW ≈ 1073 Da, while sequence/supplier listings often give ≈ C₄₁H₇₀N₁₆O₁₆S, MW ≈ 1075 Da. Developed by Lipotec (~2006) as a longer analogue of the SNAP-25 N-terminal fragment that defines Argireline. The class mechanism is competitive SNARE-complex destabilization reducing acetylcholine exocytosis, distinct from and far weaker than botulinum toxin.
TopicalCosmetic ingredient · not a drug
2–10%Typical formulation blend (cosmetic)
Thin dataDirect SNAP-8 evidence limited
~1073–1075Da · formula source-dependent
Status
Cosmetic ingredient · not FDA-approved · topical only
A cosmetic peptide with thin direct evidence and identity ambiguity.
SNAP-8 is a skin-care ingredient, full stop — not an injectable, not a drug, not topical Botox. Two honesty flags shape this entire page. First, its public-database identity is inconsistent: the formula and molecular weight differ across sources, so any build should require a supplier certificate of analysis (COA). Second, independent human evidence for SNAP-8 itself is limited; most mechanistic confidence is borrowed from its better-studied sibling Argireline. The biology is plausible; the proof for this specific molecule is thin.
💆
Primary use case
Expression lines
Topical cosmetic support for the look of forehead, glabellar, and periocular expression lines. Grade D.
🔌
Mechanism headline
SNARE-mimetic
Proposed SNAP-25/SNARE interference reducing acetylcholine-release signaling, by analogy to Argireline. Grade P.
📉
Evidence tier
Thin / borrowed
Direct SNAP-8 evidence is thin; confidence is extrapolated from Argireline and in-vitro SNARE work. Grade D/P.
⚗️
Typical use range
2–10% blend
Formulations commonly discuss a 2–10% ingredient blend in leave-on topicals — formulation guidance, not medical dosing. Grade D.
🚧
Key limitation
Skin penetration
Large, hydrophilic peptides penetrate the stratum corneum poorly; delivery may determine real-world effect. Grade P/D.
⚠️
Key risk
Irritation / claims
Skin/eye-area irritation, sensitization, and misleading "Botox alternative" marketing claims. Grade D.
🆔
Identity flag
Verify by COA
Public records conflict on formula/MW and terminal residue — confirm against supplier COA before relying on identity. Grade D.
🏷️
Regulatory status
Cosmetic only
Cosmetic ingredient / research-chemical context; not an FDA-approved therapeutic drug. Grade D.
02 · Mechanism of action
How SNAP-8 is proposed to soften expression lines.
SNAP-8's story is a hypothesis built on a sibling's evidence. The class idea: a peptide mimicking the N-terminus of SNAP-25 competes within the SNARE complex that drives synaptic-vesicle fusion, slightly reducing acetylcholine release and thus the intensity of repetitive facial-muscle contraction — softening dynamic wrinkles. This is better supported for Argireline (acetyl hexapeptide-8) than for SNAP-8 specifically, and at every step the effect is far weaker than botulinum toxin and gated by whether the peptide even reaches its target through skin. Most nodes here are Grade P (mechanistic) or D (cosmetic).
Grade P
🧩
1 · SNARE-complex competition
SNAP-8 is marketed to soften expression lines by reducing the visible effect of repetitive muscle contraction.
Clinical significance: The proposed cosmetic relevance is reduced dynamic-wrinkle appearance via partial modulation of neuromuscular signaling in superficial expression-line regions. This positioning is cosmetic, targeting the look of dynamic lines rather than skin structure.
Molecular detail: A SNAP-25-like motif is hypothesized to interfere with SNARE assembly/stability. For the sibling Argireline, the peptide competes with SNAP-25 for VAMP binding, destabilizing the ternary SNARE complex and inhibiting neuronal exocytosis; SNAP-8 is presumed to act similarly but lacks independent clinical confirmation.
Grade P
⚡
2 · Acetylcholine-release modulation
If the nerve-to-muscle signal is softened, expression lines may look less deep.
Clinical significance: The cosmetic relevance is strongest for dynamic facial lines, not structural laxity or static wrinkles. Reduced ACh release at the neuromuscular junction would lessen contraction intensity.
Molecular detail: In-vitro and related-peptide studies show SNARE-targeting peptides can inhibit Ca²⁺-dependent neurotransmitter/catecholamine release from chromaffin-cell models, though potency is far below botulinum toxin and skin delivery is limiting. Mechanistically plausible; not validated as a drug effect for SNAP-8.
Grade P/D
🚧
3 · Penetration-limited local action
SNAP-8 must get through the skin barrier to matter — and that is a major limitation.
Clinical significance: Large, hydrophilic peptides have low passive penetration across the stratum corneum, so formulation technology may determine real-world effect. Penetration is a central limitation for this peptide class.
Molecular detail: Acetyl hexapeptide-8 penetration studies show peptide size, hydrophilicity, and vehicle composition control delivery — and SNAP-8 is larger than Argireline-like hexapeptides, so the limitation likely applies at least as strongly. Direct SNAP-8 skin PK is not established.
Grade D
✨
4 · Expression-line optical smoothing
The most realistic outcome is modest visible smoothing, not paralysis.
Clinical significance: Expected cosmetic endpoints are wrinkle depth, surface roughness, crow's-foot appearance, and photo-based scoring — not muscle paralysis. The realistic claim is appearance, not function.
Molecular detail: Optical profilometry, silicone replicas, and image analysis are the proper endpoints. Much SNAP-8 efficacy framing relies on manufacturer or non-peer-reviewed claims, so this node is plausible but thinly evidenced for SNAP-8 specifically.
Grade D
💧
5 · Synergy with hydration / barrier actives
SNAP-8 may look better in formulas that also hydrate and smooth skin texture.
Clinical significance: Humectants, niacinamide, panthenol, and glycerin can reduce visible fine lines independent of any neuromodulation. Hydration-driven smoothing can confound peptide-specific wrinkle outcomes.
Molecular detail: Hydration-induced stratum-corneum swelling improves optical smoothness, which in multi-ingredient formulas is easily mistaken for a peptide effect. SNAP-8's isolated contribution in such formulas is uncertain — a key reason to be skeptical of before/after claims.
Grade P/D
🚫
6 · Botulinum-adjacent, NOT botulinum-equivalent
SNAP-8 should not be presented as topical Botox.
Clinical significance: Botulinum toxin enzymatically cleaves SNAP-25 after injection; SNAP-8 is a topical cosmetic peptide with limited delivery and no approved therapeutic label. The "topical Botox" framing is misleading.
Molecular detail: BoNT is an intracellular protease; SNARE-mimetic peptides instead compete with/interfere in SNARE assembly — a fundamentally different and much weaker mechanism. Argireline's acute toxicity is orders of magnitude lower than BoNT, reflecting how much gentler (and weaker) the peptide action is. The difference is established; clinical equivalence is not.
03 · Formulation modeling (cosmetic · no medical dosing)
Formulation use — not a clinical dose.
SNAP-8 has no approved medical dosing protocol, so the correct framing here is cosmetic formulation modeling, not clinical dosing. Everything below describes how the ingredient is used in leave-on topical products at a percentage of the finished formula — and how to convert a diluted stock solution into a batch. Injectable, oral, IV, IM, subcutaneous, and intranasal routes are not established and are not built. The calculator is a topical formulation tool, not a reconstitution-for-injection tool.
Cosmetic only · no approved medical dosing
SNAP-8 is a cosmetic ingredient, not an FDA-approved drug; it carries no therapeutic indication; FDA's current 503A nominated-bulk-substances list does not name SNAP-8/acetyl octapeptide-3 503A list. Direct human evidence for SNAP-8 is limited and mechanism is extrapolated from Argireline/SNARE literature. Cosmetic-use claims must avoid disease-treatment or drug-like neuromuscular language; "topical Botox" is a marketing claim, not a medical one.
Delivery limitation
Topical peptide penetration is likely limited by molecular size, polarity, and vehicle; related acetyl hexapeptide-8 work shows skin penetration is a central limitation. Human Cmax, Tmax, systemic bioavailability, clearance, and half-life for SNAP-8 are not established — there is no systemic PK because it is a surface cosmetic.
Topical leave-on serum (expression-line zones)
Cosmetic use model · not a medical dose
Grade D
Starting use
1× daily to expression-line zones for 7–14 days; patch test first.
Escalation
If no irritation, increase to 2× daily.
Concentration ladder
2% → 5% → 10% ingredient blend in finished formula.
Assessment cycle
8–12 weeks before judging effect; continue only if visible benefit and no irritation.
Monitoring
Redness, burning, dryness, eyelid irritation, new acneiform reaction, dermatitis.
Avoid mucosal/ocular contact and broken skin. Cosmetic appearance support only — not a drug effect. Grade D.
Concentration bands
Topical formulation bands (% of finished formula)
Band
Finished %
≈ blend per 1 g
Basis
Low
2%
20 mg/g
Conservative cosmetic intro
Standard
5%
50 mg/g
Common middle target
High
10%
100 mg/g
Marketing ceiling — not a medical dose
If a supplier sells a "10% SNAP-8 solution," that usually means the raw material itself is diluted. A 5% finished formula made from 10% stock contributes ~0.5% nominal peptide-equivalent — assuming the stock label is accurate.
SNAP-8 is a topical cosmetic ingredient. There is no basis for any injected or systemic route. Grade D.
Route reality
Topical is the only supported route
Route
Status
Topical leave-on
Cosmetic-supported
Microneedle
Research only
Oral / SC / IM / IV / intranasal
Unsupported
L2 · Topical formulation math (cosmetic only)
Topical Formulation Calculator
This is a topical formulation calculator — not an injection/reconstitution tool. It converts a target finished-formula percentage into grams of stock solution for a given batch size: grams stock = (target % ÷ stock %) × batch size. SNAP-8 is a cosmetic ingredient with no approved medical dosing; nothing here is a drug dose. Confirm the actual peptide content of any "stock %" against a supplier COA.
Stock to add
—
Base to add
—
Peptide-equiv.
—
Target check
—
Basis
—
04 · Combinations
Combinations — cosmetic formulas, not stacks.
In cosmetic practice SNAP-8 rarely appears alone — it's blended with other peptides and hydration actives. That's useful for a product but a problem for attribution: in a multi-ingredient serum, you can't tell what (if anything) the SNAP-8 contributed. Every combination below is Grade D, and the honest theme is that visible improvement is often driven by hydration, other peptides, or retinoids with far stronger evidence — not necessarily SNAP-8.
SNAP-8 + Argireline (acetyl hexapeptide-8)
Same family
SNAP-8ArgirelineSNARE family
The same neuromodulating cosmetic family, both mimicking the SNAP-25 N-terminus. Argireline has the stronger mechanistic literature base of the two; pairing them is common in "expression-line" formulas but risks redundant claims and added irritation from formula load. Do not market as a Botox replacement. Grade D/P.
Peptide
Length
Evidence
Argireline
6 aa
Stronger (still cosmetic)
SNAP-8
8 aa
Thinner
SNAP-8 + Matrixyl (palmitoyl pentapeptide-4)
Different lane
SNAP-8MatrixylECM signaling
Combines expression-line positioning (SNAP-8) with matrix/collagen-signaling positioning (Matrixyl). The two target different cosmetic mechanisms, which is the rationale — but multi-ingredient formulas make efficacy attribution to either peptide difficult. Grade D.
Component
Cosmetic role
SNAP-8
Dynamic-line appearance
Matrixyl
Texture / matrix support
SNAP-8 + Hyaluronic acid / glycerin / panthenol
Hydration confounder
SNAP-8HAGlycerin
Hydration improves fine-line appearance and product tolerability — which is genuinely useful, but means visible improvement may be hydration-driven rather than peptide-specific. This is a key confounder in cosmetic peptide outcomes. Grade D.
Element
Effect
Humectants
Optical smoothing via hydration
SNAP-8
Uncertain isolated contribution
SNAP-8 + Retinoid / retinal / retinol
Irritation caution
SNAP-8Retinoid
Retinoids have far stronger evidence for photoaging than any cosmetic peptide; here SNAP-8 would be the adjunct, not the driver. The combination raises irritation — separate timing, reduce actives, and avoid on compromised skin. Grade D.
Component
Note
Retinoid
Stronger photoaging evidence
SNAP-8
Cosmetic adjunct; more irritation together
Hard-constraint note — Do not combine SNAP-8 with procedures, injectables, acids, retinoids, or microneedling on broken or irritated skin except under professional guidance. Do not market topical SNAP-8 as equivalent to botulinum toxin — it is a cosmetic ingredient with limited delivery and no approved therapeutic indication. In any multi-ingredient formula, treat visible benefit as a property of the whole product, not proof of a SNAP-8 effect.
05 · Safety & contraindications
Generally gentle — but watch the claims and the eyes.
As a topical cosmetic peptide, SNAP-8's safety profile is mostly the ordinary risk of any leave-on skincare active: irritation, dryness, and the possibility of contact sensitization — and the unusually high acute-toxicity margin of its sibling Argireline (LD₅₀ ≥2000 mg/kg vs botulinum toxin's ~20 ng/kg) reflects how gentle, and how weak, this class is. The bigger issues are the eye area, where periocular application demands real caution, and the compliance risk of "Botox alternative" marketing. Systemic neuromuscular effects are not established for topical cosmetic use.
Contact dermatitis / sensitizationGeneral topical-product risk, especially in sensitive skin. Grade D.
Eye irritationIf applied too close to the ocular surface — tearing, blurring, eyelid swelling. Route-specific risk. Grade D.
Dryness / barrier disruptionEspecially when combined with retinoids or acids. Grade D.
Systemic neuromuscular effectsNot established for topical cosmetic use. Grade P/D.
Misleading "Botox alternative" claimsHigh compliance/expectation risk; the effect is cosmetic appearance, not paralysis. Grade D.
Identity / quality uncertaintyFormula/MW ambiguity across databases — verify by COA. Grade D.
Low acute toxicity (class)The Argireline class shows a very high acute-toxicity margin — gentle, and correspondingly weak. Grade P.
Practical safety framework
Patch test, then watch the first two weeks
Most reactions are irritation or contact sensitization that show up early. Patch test before facial use, start once daily, and hold if redness or burning persists beyond a day or two. The CIR safety context for related acetyl hexapeptides supports a low-irritation expectation but not a zero-risk one.
The eye area is the high-caution zone
Periocular skin is thin and the ocular surface is nearby. Apply outside the orbital rim only, prefer lower strengths, and stop immediately for any tearing, blurred vision, or eyelid swelling.
Claims are a safety issue too
Presenting SNAP-8 as "topical Botox" sets up false expectations and crosses into drug-like claims it can't support. The honest framing is modest cosmetic appearance support, with benefit judged by photos over 8–12 weeks.
Contraindications & cautions
Condition / scenario
Concern
Severity
Known allergy to formula ingredients
Contact dermatitis
High
Eye disease / recent eye surgery
Eye-area irritation risk
High
Expectation of Botox-like effect
Misleading efficacy / compliance risk
High (claims)
Active dermatitis / eczema flare
Irritation, worse barrier
Moderate
Broken skin / wounds
Irritation / contamination risk
Moderate
Pregnancy / lactation
Lack of direct safety data
Moderate
Recent laser / peel / microneedling
Compromised barrier
Moderate
Concurrent strong retinoids / acids
Additive irritation
Moderate
History of cosmetic sensitivity
Higher intolerance risk
Moderate
Immunocompromised / infected skin
Avoid nonessential actives
Moderate
Unverified product identity
Formula/MW/purity uncertainty
Verify COA
Any injected / systemic route
Unsupported for a cosmetic
Avoid
06 · Evidence base
Thin for SNAP-8 — borrowed from Argireline.
This is the most important honesty section on the page. Independent, peer-reviewed human evidence for SNAP-8 specifically is thin and often manufacturer-driven. What gives the molecule its plausibility is the better-studied sibling Argireline (acetyl hexapeptide-8): mechanistic SNARE/neurotransmitter-release work, skin-penetration studies, a small clinical pilot, and cosmetic-regimen trials — none of which is direct proof for SNAP-8. The honest grade is low to very low (D/P): real mechanism, real sibling data, thin direct validation.
SNAP-8 direct
Thin
Independent peer-reviewed SNAP-8-specific human efficacy data are limited; claims often manufacturer-driven. Grade D.
In-vitro skin-penetration work shows delivery is a central limit for these peptides. Grade P.
Mechanism
SNARE
Combinatorial-library work identified SNARE-assembly-inhibiting peptides. Grade P.
DSNAP-8 · cosmetic claims
SNAP-8 direct evidence — manufacturer / cosmetic claim studies
Direct SNAP-8 testing is typically topical cosmetic evaluation with limited public, independent, peer-reviewed detail. Marketing sometimes cites wrinkle-depth reductions, but independent replication is limited — the reason SNAP-8's own grade stays low despite a plausible mechanism.
Blanes-Mira et al. 2002 — a synthetic hexapeptide with antiwrinkle activity
The foundational Argireline work: characterized SNARE-inhibition mechanism in neurosecretory models and reported anti-wrinkle activity, with a small clinical component (10% solution, n=10) showing ~30% periorbital wrinkle-depth reduction. The strongest evidentiary anchor for the class — but for the sibling, not SNAP-8.
SNARE-complex modulators from a constrained combinatorial library (2003)
Identified α-helix-constrained peptides that inhibit SNARE core-complex assembly and exocytosis — the molecular foundation for designing SNAP-25-mimetic cosmetic peptides like Argireline and, by extension, SNAP-8.
Bhargava et al. 2006 — acetyl hexapeptide SNARE inhibition
Showed the acetyl hexapeptide inhibited SNARE-complex formation in a cell-free system and reduced catecholamine release from chromaffin cells by up to ~40% at micromolar concentrations — confirming competition with native SNAP-25 rather than enzymatic cleavage, the key mechanistic distinction from botulinum toxin. Bhargava 2006.
Acetyl hexapeptide-8 in cosmeceuticals — permeability & efficacy review (2025)
Reviews preclinical/clinical signals for AH-8 (possible wrinkle-depth, elasticity, hydration effects) while emphasizing that low skin penetration limits bioavailability and that mechanisms remain incompletely understood — supporting Argireline as a comparator, not as proof for SNAP-8. INCI reference.
In-vitro skin penetration of acetyl hexapeptide-8 (2015)
Demonstrated the penetration/delivery limitations relevant to topical peptide claims — peptide size, hydrophilicity, and vehicle composition control delivery. Directly relevant to SNAP-8, which is larger than Argireline-like hexapeptides and likely at least as penetration-limited.
Enhanced skin permeation of anti-wrinkle peptides via molecular modification
Argireline as a Botox-mimetic acetyl hexapeptide that competes with SNAP-25 for VAMP binding and destabilizes the SNARE complex; the work pursues molecular modification to improve the poor passive skin permeation that limits this whole peptide class. permeation study.
Topical acetyl hexapeptide-8 in blepharospasm — pilot (2012)
A small topical AH-8 clinical pilot exploring the peptide as a SNAP-25 inhibitor for blepharospasm — interesting as the closest thing to a therapeutic test of the class, but for AH-8, not SNAP-8, and far from a definitive trial.
Open-label peptide serum regimen for expression lines (n=29, 2016)
An open-label cosmetic regimen study where a multi-ingredient peptide serum improved photodamaged-skin endpoints — useful as cosmetic context, but the design cannot isolate SNAP-8's contribution from the rest of the regimen.
CIR safety assessment — acetyl hexapeptide-8 & related ingredients
The Cosmetic Ingredient Review dossier covers in-vitro SNARE/catecholamine-release context and cosmetic safety for related acetyl hexapeptides — supporting mechanistic plausibility and a low-irritation expectation, but explicitly not therapeutic dosing or SNAP-8-specific claims.
Acetyl octapeptide-3 — PubChem / FDA GInAS identity records
Public substance records (PubChem CID 71587832; FDA GInAS) document SNAP-8's chemical identity — but with formula/terminal-residue ambiguity across sources and no therapeutic approval. The basis for the page's verify-by-COA caution. identity records.
GRADE summary — Overall evidence strength for SNAP-8 is low to very low for independent human efficacy. The mechanism is plausible by analogy to Argireline/acetyl hexapeptide-8 and SNARE-targeting peptide research, but direct SNAP-8 clinical data are thin, often manufacturer-driven, and not equivalent to drug-level trials. The honest grade is D/P, with no approved medical dosing, no systemic PK, and no validated biomarker scaffold. Positioning: "a plausible cosmetic peptide whose specific evidence is thin — best understood through its better-studied sibling, and never as topical Botox."
07 · Compare & contrast
SNAP-8 among the cosmetic peptides.
SNAP-8 sits in the neuromodulating ("Botox-alternative") lane of cosmetic peptides, next to its stronger-evidenced sibling Argireline. The other major cosmetic-peptide lanes work differently: Matrixyl signals the extracellular matrix; GHK-Cu drives remodeling/repair. None of these is a drug, and none is a substitute for botulinum toxin — the table keeps mechanism class and the (cosmetic) evidence tier honest.
L1 · Consumer — SNAP-8 is a topical cosmetic peptide used in anti-aging formulas for the appearance of expression lines. It's best understood as a skin-care ingredient that may modestly soften the look of fine lines — not as topical Botox and not a medical treatment. The evidence for SNAP-8 itself is thin, so set expectations accordingly, patch test, and judge any product over a couple of months.
L2 · Clinical — SNAP-8 / acetyl octapeptide-3 is a synthetic octapeptide marketed for dynamic-wrinkle appearance via a proposed SNAP-25/SNARE-modulating mechanism. Human evidence is thin, direct pharmacokinetics aren't established, and skin penetration is a real limitation. Any use should be framed as cosmetic topical support with irritation monitoring — not a drug effect, and not equivalent to botulinum toxin.
L3 · Research — SNAP-8 is an Argireline-adjacent SNAP-25/SNARE-mimetic, commonly represented as Ac-EEMQRRAD-NH₂, though public identity records show formula/terminal-residue ambiguity (verify by COA). Mechanistic plausibility derives from SNARE-complex assembly and neurotransmitter-release studies in related peptides; SNAP-8-specific independent clinical validation remains limited, and delivery across the stratum corneum is the central open question.
08 · References & evidence
Source register.
Evidence grades reflect the strength of support for the specific claim cited, not the prestige of the journal. For SNAP-8 the honest picture is mostly Grade D (cosmetic/identity/regulatory) and Grade P (mechanistic, largely via Argireline and SNARE work), with a single Grade-B item that belongs to a related peptide (AH-8), not SNAP-8. Much of the register is intentionally about the sibling molecule — because that, not SNAP-8 itself, is where the real evidence lives.